Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo‐controlled crossover study

Abstract

Ecopipam reduced tics and was well tolerated. This placebo-controlled study of ecopipam supports further clinical trials in children and adolescents with Tourette syndrome. © 2018 International Parkinson and Movement Disorder Society.